



#brexit

UK Banks

Running the numbers on 'No-Deal' Brexit

As the likelihood of 'No-Deal' Brexit appears to have grown, we try to calibrate the earnings impact of 'No-Deal' on UK banks and what is in the price. Our estimates in such a scenario show a c.30-40% EPS cut for Lloyds, RBS and CYBG in 2020; with stocks trading at c.11.5x 'No-Deal' EPS they are close to pricing in this scenario, we think. We acknowledge that lower trough earnings, a worse economic impact of 'No-Deal' or a change of Government might mean stocks go lower.

We focus on four key questions in this report:

- **What would happen to the economy in 'No-Deal'?** We draw on our UK Economics team's work and look at an orderly 'No-Deal' scenario with a mild recession. This assumes a reversion to WTO trading rules, zero headline GDP growth by 2020, inflation peaking at 3.5%, unemployment rising to 6% and a BOE rate cut. For full details see *UK Themes: Alternative Brexit scenario: A No-Deal rate cut*.
- **How would 'No-Deal' translate into UK banks earnings/dividends?** Our simulation suggests 'No-Deal' could mean a c.30-40% EPS cut for Lloyds, RBS and CYBG and c.9% for HSBC. Our 'No-Deal' scenario factors in lower policy rates dragging on net interest margins, higher unemployment driving UK impairment charges to around double the base case and loan growth being more subdued. We model 'No-Deal' 2020 dividends as flat at 2018 levels and buybacks being cancelled (ex-HSBC).
- **Does now represent a good entry point?** We think so; on the 'No-Deal' earnings estimates Lloyds and RBS trade on c.11.5x 2020e EPS. Looking at the last 20+ years of trading history for Lloyds, RBS and HSBC shows the stocks on average trade at c.10-11x 12m forward EPS. On a longer-term view, buying trough earnings at a cross-cycle multiple looks good value to us. We also note that Lloyds with a covered dividend and yield of 5.6% looks appealing (RBS/CYBG both at c.3% however). For our initial take see *UK Banks No-Deal Brexit risks rising but 40% EPS cut already priced in* (15 Nov 2018).
- **What else could happen to drive stock prices lower?** We see lower trough multiples, worse 'No-Deal' impact, or a change in Government as key risks. We explore in this report some of the pushback we have had on our view – for more see *UK Banks: Top 5 pushbacks to our No-Deal Brexit view* (19 Nov 2018)

On our central case RBS and Lloyds trade at sub 7x 2020e EPS. While uncertainty is still running high, we continue to expect the withdrawal agreement to be ratified and in that central scenario OW-rated Lloyds and RBS offer c.50% potential upside to our price targets from here. For our economists' take see *UK Economics Research: Brexit update #11: Returning with a better deal*, 22 Nov 2018.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.

PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 13.

Equity Research

27 November 2018

INDUSTRY UPDATE

European Banks

NEUTRAL

Unchanged

European Banks

Chris Manners

+44 (0)20 7773 2136

chris.manners@barclays.com

Barclays, UK

Aman Rakkar, CFA

+44 (0)20 3555 1425

aman.rakkar@barclays.com

Barclays, UK

What does a 'No-Deal' scenario look like?

For No-Deal, we use our UK Economics teams' scenario, see: *UK Themes: Alternative Brexit scenario: A No-Deal rate cut*. This entails inflation rising to 3.5%, growth slowing to 0% with risks of recession; unemployment rising above 6%, and a Bank Rate cut to 25bp.

FIGURE 1
Barclays Economics Research: No-Deal vs. Base case

	No-deal scenario				Basecase scenario				Difference		
	2017	2018e	2019e	2020e	2017	2018e	2019e	2020e	2018e	2019e	2020e
Real GDP, y/y	1.7%	1.3%	0.5%	0.2%	1.7%	1.3%	1.3%	1.4%	0.0%	-0.8%	-1.2%
Unemployment rate, %	4.4%	4.2%	4.8%	6.0%	4.4%	4.2%	4.8%	5.0%	0.0%	0.0%	1.0%
CPI inflation, y/y	2.7%	2.5%	3.5%	2.9%	2.7%	2.5%	2.0%	2.0%	0.0%	1.5%	0.9%
Bank Rate (EOP)	0.50%	0.75%	0.25%	0.25%	0.50%	0.75%	0.75%	0.75%	0.00%	-0.50%	-0.50%

Source: Barclays Economics Research

FIGURE 2
Real growth slowing to zero, risk of recession




FIGURE 3
Unemployment rising to 6% by 2020




FIGURE 4
Inflation spiking to 3.5% in 2019





FIGURE 5
Bank Rate cut to 0.25%



Source for all charts: Barclays Economics Research estimates

What would that mean for UK banks' earnings?

Our simulation suggests this could equate to a c.40% EPS cut for Lloyds/RBS and 9% for HSBC. Our scenario involves:

- Impairments 30-100% higher than base case, with 2020e UK impairment charge rising above 50bp, from c30bp;
- Net interest margins 10-30bp lower than 2020e base-case, assuming rates are cuts
- Loan growth/costs broadly unchanged, vs. base-case
- Ordinary dividends maintained at the 2018e level, with specials/buybacks cancelled

FIGURE 6

No-Deal vs. base case P&L for key UK Banks

	Base-case scenario				No-deal scenario				% chg			
	Lloyds (£m)	RBS (£m)	HSBC (\$m)	CYBG (£m)	Lloyds (£m)	RBS (£m)	HSBC (\$m)	CYBG (£m)	Lloyds (£m)	RBS (£m)	HSBC (\$m)	CYBG (£m)
Total income	18,064	13,585	61,233	1,675	16,755	12,754	59,730	1,564	-7%	-6%	-2%	-7%
Expenses	-8,133	-6,998	-35,534	-914	-8,139	-7,216	-34,901	-909	0%	3%	-2%	-1%
Pre-provision profit	9,930	6,587	25,699	761	8,616	5,537	24,829	655	-13%	-16%	-3%	-14%
Impairment	-1,491	-1,053	-3,267	-187	-3,115	-1,830	-4,166	-245	109%	74%	27%	31%
Associates/other	0	0	2,524	0	0	0	2,524	0	nm	nm	0%	nm
Profit before tax	8,439	5,533	24,955	574	5,500	3,708	23,188	410	-35%	-33%	-7%	-29%
Tax	-2,278	-1,521	-5,380	-149	-1,485	-1,010	-5,101	-107	-35%	-34%	-5%	-29%
AT1s etc	-403	-300	-2,387	-54	-403	-300	-2,387	-54	0%	0%	0%	0%
Attributable profit	5,757	3,712	17,189	371	3,612	2,398	15,700	250	-37%	-35%	-9%	-33%
EPS	8.5	32.8	0.85	25.9	4.9	19.5	0.78	17.4	-42%	-40%	-9%	-33%
Ordinary DPS	3.8	10.0	0.51	12.0	3.2	6.0	0.51	8.0	-14%	-40%	0%	-33%
Payout ratio	44%	31%	60%	46%	65%	31%	66%	46%	47%	1%	9%	-1%
CET1 ratio	13.9%	14.0%	15.4%	13.0%	13.6%	14.9%	15.0%	12.3%	-3%	7%	-3%	-5%
NIM	3.00%	2.06%	1.81%	1.62%	2.70%	1.94%	1.77%	1.52%	-10%	-6%	-2%	-6%
Loan growth	-0.3%	1.7%	3.8%	4.9%	-0.3%	-0.3%	3.5%	3.6%	-1%	-116%	-8%	-27%
Cost/income ratio	45.0%	51.0%	58.0%	54.6%	48.6%	56.1%	59.2%	58.1%	8%	10%	2%	7%
Impairment charge	0.33%	0.31%	0.31%	0.24%	0.69%	0.56%	0.39%	0.32%	110%	82%	27%	34%

Source: Barclays Research estimates

FIGURE 7
2020e EPS change – No-Deal vs. base case




FIGURE 8
2020e DPS change – No deal vs. base case




FIGURE 9
No deal vs. base case net interest margins (2020e)




FIGURE 10
No deal vs. base case impairment charges (2020e)






FIGURE 11
No deal vs. base case loan growth, 3yr CAGR



Source: Barclays Research estimates

FIGURE 12
No deal vs. base case cost income ratio (2020e)



Source: Barclays Research estimates


Is now a good entry point?

We think that current prices offer good risk-reward for Lloyds and RBS, as it looks like stocks are trading just above cross-cycle multiples on potential trough EPS in our 'No-Deal' scenario. We see 50%+ potential upside to stocks over time in the central case of a deal being agreed, although we acknowledge that uncertainty is high and multiples could trough lower than the cross-cycle average, meaning stocks could have more downside before value reasserts itself.

On our 'No-Deal' earnings estimates, Lloyds and RBS trade on c11.5x 2020e EPS... Our 'No-Deal' earnings estimates, as calibrated above, are c.40% below the base case for the domestic banks. On this basis the stocks are trading at c.11-12x 2020e EPS vs c.7x 2020e EPS on the base case.


... which is close to the cross-cycle multiple over the last 20-30 years. Overleaf we look at the last 20+ years of trading history for Lloyds, RBS and HSBC, which indicates that the stocks on average trade at c.10-11x 12m forward EPS. On a longer-term view, buying trough earnings at a close to cross-cycle multiple looks good value to us. We do note that in the run-up to previous recessions multiples troughed at low single-digit levels as the market discounted negative earnings revisions before consensus reacted.

FIGURE 13
UK domestic banks trading at 11-12x No-Deal earnings, vs. c7x base case...



Source: Barclays Research estimates

FIGURE 14
...With 3-6% ordinary dividend yields in No-Deal, vs. 6-7% base-case



Source: Barclays Research estimates

UK banks long-run earnings multiples

FIGURE 15
Lloyds typically trades at 10.5x 12m forward earnings




FIGURE 16
RBS also typically trades at 10.5x 12m forward earnings





FIGURE 17
HSBC typically trades at 11.4x 12m forward earnings



Source for all charts: DataStream, 12m fwd earnings based on Thomson Reuters consensus, Barclays Research

What else could drive stock prices lower?

As we debated in our report on Monday 19th November, see *UK Banks: Top 5 pushbacks to our No-Deal Brexit view*, there are a few recurrent pushbacks to our view that current prices offer a good entry point:

1. Will your assumption that the P/E multiple of 10-11x through the cycle offer a decent entry point hold?

Investors are concerned that even if our 'No-Deal' 2020 EPS estimates of 4.9p for Lloyds and 20p for RBS prove ultimately correct, the market would still penalise the stocks with a lower multiple to account for the uncertainty (e.g. in 2011/12 Lloyds and RBS hit 5-7x forward EPS as investors digested risk of a double-dip UK recession and the Eurozone crisis). Other investors expect that the market, when it has asset quality concerns, would flip to using a price-to-tangible book lens and note that Lloyds is still trading above 1x TNAV.

Our take: we acknowledge that the market could overreact, but do expect multiples to revert to historical averages over time, and we think that paying an average multiple on trough earnings could prove good value.

2. Couldn't a recession and economic impact of 'No-Deal' be worse than you assume?

We base our assumptions of zero loan growth, 70bps cost of risk and 2.70% net interest margin for Lloyds by 2020 on our UK economists' scenario of a mild recession caused by No-Deal with CPI at 3.5% (tariffs/sterling moves), unemployment of 6%, zero GDP growth and lower policy rates by 2020. We have had investors suggesting that 'No-Deal' could be significantly worse than this baseline or be more prolonged.

Our take: it's fair to say that the depth of any potential recession is highly uncertain and for a more severe outcome one could look at BOE/EBA stress test results to assess outcomes, and *recent BOE comments* suggest that Lloyds, RBS and HSBC would be resilient to severe economic and market stress

3. What if there were a general election and a Labour government were elected – wouldn't stocks fall further?

Given the 2017 Labour party manifesto talked about launching a consultation to break up RBS to "create new local public banks that are better matched to their customers' needs", investors are concerned firstly about how / if a nationalization might happen and secondly what impact that could have on profitability across the UK banking sector. They are also concerned about other potential policies and the impact on the competitiveness of the UK economy overall.

Our take: at the moment we do not expect that conservative MPs would back a general election given the 2/3rd majority needed under the fixed term Parliament Act to call a general election and that a vote of no confidence is unlikely. However, we think there could be further downside to UK bank stocks if there were a general election and a Labour government were elected.

4. Wouldn't the banks' 2020 earnings trough lower than you forecast in 'No-Deal' due to the pro-cyclical nature of the new accounting standard IFRS 9 causing provision front-loading?

The new accounting standard extant as of 1 Jan 2018 means that banks need to recognise 'expected' losses as well as incurred losses by taking lifetime impairment charges on 'significantly deteriorated' loans known as Stage 2 loans. This acceleration of loss recognition could mean banks start to report much lower trough earnings and cut dividends etc vs our estimates.

Our take: given the transitional relief available on capital ratios from the PRA and the fact that investors will know how much provisioning has been brought forward, we expect the market to look through the stage 1&2 impairments to the incurred/stage 3 losses. We do flag though that this is untested and banks could show some lumpy quarters of losses and so careful explanations will be needed from management teams and regulators.

5. Lloyds (-16%) and RBS (-19%) stocks have outperformed the SX7P European banks index (-21%) YTD, so shouldn't they underperform from here?

The recent moves since November 14th were a big catch-up trade for Lloyds and RBS but given the elevated risk shouldn't the major domestic banks underperform European peers?

Our take: on the central case Lloyds and RBS have had c.5% positive EPS revisions ytd, vs European banks c.-5% so the relative derating has been material, we also note idiosyncratic reasons (Italy, Turkey, EU rates, Trade Tension, AML etc) why EU banks have been weak.

Comparing UK banks to the sector

FIGURE 18
Sector 2020e P/E




FIGURE 19
Barclays vs. Consensus EPS




FIGURE 20
2018e PTBV vs 2020e RoTE




FIGURE 24

Our Top Pick is Lloyds (OW) and we're most cautious on Standard Chartered (UW) and CYBG (UW)

Preference		Price	Sellside	Capital/dividends	Valuation			2018e	2019e	2020e
Order	Stock		Sentiment		TNAV/shr	EPS				
1	Lloyds	Price Target	90p Buyers	52% CET1 ratio (18e)	14.6% TNAV (18e)	52.0p BARCe	8.0p	8.1p	8.6p	
		Price (last)	57p Holders	26% T1 Lev ratio (18e)	5.3% P/TNAV	1.1x Cons.	7.7p	7.8p	8.0p	
OW	Mkt cap	Up/downside	57% Sellers	22% DPS, (h/line 19e)	3.5p RoTE (20e)	16.3% Be vs C.	3%	4%	7%	
	£40.7bn	26/11/2018		Divi yield	6.1%	P/BARCe	7.2x	7.1x	6.6x	
2	RBS	Price Target	340p Buyers	71% CET1 ratio (18e)	16.5% TNAV (18e)	286.0p BARCe	26.9p	29.1p	34.3p	
		Price (last)	225p Holders	24% T1 Lev ratio (18e)	5.3% P/TNAV	0.8x Cons.	28.0p	28.0p	32.1p	
OW	Mkt cap	Up/downside	51% Sellers	5% DPS, (h/line 19e)	20.0p RoTE (20e)	12.1% Be vs C.	-4%	4%	7%	
	£26.6bn	26/11/2018		Divi yield	8.9%	P/BARCe	8.4x	7.7x	6.6x	
3	HSBC	Price Target	740p Buyers	32% CET1 ratio (18e)	14.4% TNAV (18e)	\$7.08 BARCe	\$0.79	\$0.82	\$0.85	
		Price (last)	674p Holders	59% T1 Lev ratio (18e)	4.7% P/TNAV	1.2x Cons.	\$0.73	\$0.76	\$0.82	
EW	Mkt cap	Up/downside	10% Sellers	9% DPS, (h/line 19e)	\$0.51 RoTE (20e)	9.5% Be vs C.	7%	8%	4%	
	£131.0bn	26/11/2018		Divi yield	5.9%	P/BARCe	11.0x	10.5x	10.1x	
4	CYBG	Price Target	240p Buyers	39% CET1 ratio (18)	13.0% TNAV (18e)	266.2p BARCe	-	23.9p	25.9p	
		Price (last)	213p Holders	39% T1 Lev ratio (18)	4.3% P/TNAV	0.8x Cons.	-	26.7p	28.2p	
UW	Mkt cap	Up/downside	13% Sellers	22% DPS, (h/line 19e)	12.0p RoTE (20e)	9.7% Be vs C.	-	-10%	-8%	
	£2.7bn	26/11/2018		Divi yield	5.6%	P/BARCe	-	8.9x	8.2x	
5	StanChart	Price Target	600p Buyers	38% CET1 ratio (18e)	14.6% TNAV (18e)	\$12.03 BARCe	\$0.71	\$0.78	\$0.84	
		Price (last)	616p Holders	29% T1 Lev ratio (18e)	5.7% P/TNAV	0.7x Cons.	\$0.73	\$0.82	\$0.91	
UW	Mkt cap	Up/downside	-3% Sellers	33% DPS, (h/line 19e)	\$0.25 RoTE (20e)	6.6% Be vs C.	-3%	-5%	-7%	
	£19.9bn	26/11/2018		Divi yield	3.2%	P/BARCe	11.1x	10.2x	9.4x	

Source: Company data, Barclays Research estimates, Thomson Reuters Consensus, Priced at 26/11/2018.

Appendix

Long-run UK impairments

FIGURE 25
2020e impairments rising to 50bp vs. 30bp base-case, vs. 2% in last two recessions




FIGURE 26
Corporates historically a key source of impairments; banks now have less exposure to costly Commercial RE




FIGURE 27
Consumer credit also a key driver of impairments, closely linked to moves in UK unemployment





FIGURE 28
Mortgage impairments expected benign, supported by low LTVs/strong house prices




Source for all charts: Aggregation of long-run company data/reports, Barclays Research estimates

UK loan exposures and book mix

FIGURE 29


UK banks' exposure to UK loans



Source: Company reports, Barclays Research, 2017

FIGURE 30

UK loan book by type



Source: Company reports, Barclays Research, 2017

ANALYST(S) CERTIFICATION(S):

We, Chris Manners and Aman Rakkar, CFA, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

Where any companies are the subject of this research report, for current important disclosures regarding those companies please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities, the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst.

Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. Such non-US research analysts may not be associated persons of Barclays Capital Inc., which is a FINRA member, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst's account.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

Materially Mentioned Stocks (Ticker, Date, Price)

CYBG PLC (CYBGC.L, 26-Nov-2018, GBp 213), Underweight/Neutral, A/CD/D/J/L

HSBC Holdings PLC (HSBA.L, 26-Nov-2018, GBp 674), Equal Weight/Neutral, CD/J/K/M/N

Lloyds Banking Group PLC (LLOY.L, 26-Nov-2018, GBp 57), Overweight/Neutral, A/CD/CE/D/E/I/J/K/L/M/N

Royal Bank of Scotland Group PLC (RBS.L, 26-Nov-2018, GBp 225), Overweight/Neutral, CD/CE/D/I/J/K/L/M/N

Standard Chartered PLC (STAN.L, 26-Nov-2018, GBp 616), Underweight/Neutral, A/CD/D/J/K/L/M/N

Prices are sourced from Thomson Reuters as of the last available closing price in the relevant trading market, unless another time and source is indicated.

Disclosure Legend:

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of the issuer in the previous 12 months.

B: An employee or non-executive director of Barclays Bank PLC and/or an affiliate is a director of this issuer.

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by this issuer.

CE: Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by this issuer.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

E: Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer within the next 3 months.

FA: Barclays Bank PLC and/or an affiliate beneficially owns 1% or more of a class of equity securities of this issuer, as calculated in accordance with US regulations.

FB: Barclays Bank PLC and/or an affiliate beneficially owns a long position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

FC: Barclays Bank PLC and/or an affiliate beneficially owns a short position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

GD: One of the analysts on the fundamental credit coverage team (or a member of his or her household) has a financial interest in the debt or equity securities of this issuer.

GE: One of the analysts on the fundamental equity coverage team (or a member of his or her household) has a financial interest in the debt or

IMPORTANT DISCLOSURES CONTINUED

equity securities of this issuer.

H: This issuer beneficially owns more than 5% of any class of common equity securities of Barclays PLC.

I: Barclays Bank PLC and/or an affiliate is party to an agreement with this issuer for the provision of financial services to Barclays Bank PLC and/or an affiliate.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities of this issuer and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from this issuer within the past 12 months.

L: This issuer is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: This issuer is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: This issuer is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

O: Not in use.

P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.

Q: Barclays Bank PLC and/or an affiliate is a Corporate Broker to this issuer.

R: Barclays Capital Canada Inc. and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

S: This issuer is a Corporate Broker to Barclays PLC.

T: Barclays Bank PLC and/or an affiliate is providing equity advisory services to this issuer.

U: The equity securities of this Canadian issuer include subordinate voting restricted shares.

V: The equity securities of this Canadian issuer include non-voting restricted shares.

Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

Stock Rating

Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Rating Suspended - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

Industry View

Positive - industry coverage universe fundamentals/valuations are improving.

Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

Negative - industry coverage universe fundamentals/valuations are deteriorating.

Below is the list of companies that constitute the "industry coverage universe":

European Banks

ABN AMRO (ABN.AS)

Bank of Ireland (BIRG.I)

Credit Suisse AG (CSGN.S)

CYBG PLC (CYBGC.L)

Danske Bank (DANSKE.CO)

Deutsche Bank (DBKGn.DE)

DNB (DNB.OL)

HSBC Holdings PLC (HSBA.L)

Lloyds Banking Group PLC (LLOY.L)

IMPORTANT DISCLOSURES CONTINUED

Nordea (NDAFI.HE)	Royal Bank of Scotland Group PLC (RBS.L)	SEB (SEBa.ST)
Standard Chartered PLC (STAN.L)	Svenska Handelsbanken (SHBa.ST)	Swedbank (SWEDa.ST)
UBS AG (UBSG.S)		

Distribution of Ratings:

Barclays Equity Research has 1555 companies under coverage.

45% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 56% of companies with this rating are investment banking clients of the Firm; 75% of the issuers with this rating have received financial services from the Firm.

38% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 47% of companies with this rating are investment banking clients of the Firm; 67% of the issuers with this rating have received financial services from the Firm.

14% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 35% of companies with this rating are investment banking clients of the Firm; 66% of the issuers with this rating have received financial services from the Firm.

Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

Top Picks:

Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. To view the current list of Top Picks, go to the Top Picks page on Barclays Live (<https://live.barcap.com/go/keyword/TopPicks>).

To see a list of companies that comprise a particular industry coverage universe, please go to <https://publicresearch.barclays.com>.

Types of investment recommendations produced by Barclays Equity Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.

Disclosure of other investment recommendations produced by Barclays Equity Research:

Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

IMPORTANT DISCLOSURES CONTINUED

CYBG PLC (CYBG LN / CYBGC.L)

GBP 213 (26-Nov-2018)

Stock Rating


UNDERWEIGHT

Industry View

NEUTRAL

Rating and Price Target Chart - GBP (as of 26-Nov-2018)

Currency=GBP



Publication Date	Closing Price	Rating	Adjusted Price Target
21-Nov-2018	2.07		2.40
22-Oct-2018	2.67	Underweight	2.80

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of CYBG PLC in the previous 12 months.

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by CYBG PLC.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from CYBG PLC in the past 12 months.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by CYBG PLC and/or in any related derivatives.

L: CYBG PLC is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

Valuation Methodology: We value UK banks using the traditional Gordon Growth model to determine a fair P/BV multiple for the franchise at Dec 2022e; we then add or subtract the capital surplus/deficit versus our steady-state capital forecast at that date and discount this back to our price target date and add the present value of dividends until the valuation date. For the UK banks we use a cost of equity of 10% and terminal EPS growth of 2%.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Risks to our price target include the following: CYBG could offset margin pressure with stronger growth (e.g. VM re-brand catalyses stronger growth).

Rate hikes could be greater / deposit betas lower than we expect.

CYBG could upgrade synergy targets (either costs, or giving detail on revenue synergies)

PPI costs could come through lower than we expect, boosting surplus capital.

Resolution of macro concerns around Brexit / politics could see the space rebound.


IMPORTANT DISCLOSURES CONTINUED

HSBC Holdings PLC (HSBA LN / HSBA.L)
GBP 674 (26-Nov-2018)

Stock Rating
EQUAL WEIGHT

Industry View
NEUTRAL

Rating and Price Target Chart - GBP (as of 26-Nov-2018)



Currency=GBP

Publication Date	Closing Price	Rating	Adjusted Price Target
07-Aug-2018	7.16		7.40
12-Jun-2018	7.33		7.50
13-Apr-2018	6.85		7.20
14-Mar-2018	6.90	Equal Weight	7.00
12-Mar-2018	7.06	Coverage Dropped	
01-Aug-2017	7.65		7.00
22-Feb-2017	6.80		6.50
05-Jan-2017	6.62		6.70
08-Nov-2016	6.20		6.00
06-Sep-2016	5.69		5.50
04-Aug-2016	5.17		5.25
25-Feb-2016	4.49		5.00

On 26-Nov-2015, prior to any intra-day change that may have been published, the rating for this security was Equal Weight, and the adjusted price target was 6.

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by HSBC Holdings PLC.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by HSBC Holdings PLC and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from HSBC Holdings PLC within the past 12 months.

M: HSBC Holdings PLC is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: HSBC Holdings PLC is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

Valuation Methodology: We value the UK banks using the traditional Gordon Growth model to determine the price to book value for franchise at Dec 2020. We then add or subtract the capital surplus/deficit versus our steady state capital forecast at that date. We discount this back to the Price Target date and add the present value of dividends until the valuation date. For the UK banks we use a cost of equity of 10% and a terminal growth of 2%.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key upside risks: Faster growth and benign credit quality in Asia together with a faster rise in US rates driving earnings and returns higher in addition to higher-than-expected capital return.

Key downside risks: Weaker Asian growth as tariff barriers weigh on trade flows, further structural challenges in investment banking and higher credit costs pose the greatest risk to our price target.


IMPORTANT DISCLOSURES CONTINUED

Lloyds Banking Group PLC (LLOY LN / LLOY.L)
GBP 57 (26-Nov-2018)

Stock Rating
OVERWEIGHT

Industry View
NEUTRAL

Rating and Price Target Chart - GBP (as of 26-Nov-2018)



Currency=GBP

Publication Date	Closing Price	Rating	Adjusted Price Target
14-Mar-2018	0.67	Overweight	0.90
12-Mar-2018	0.68	Coverage Dropped	
28-Apr-2017	0.69		0.77
05-Jan-2017	0.65	Overweight	0.75
27-Oct-2016	0.58		0.55
27-Jun-2016	0.51	Equal Weight	0.65
11-Jan-2016	0.69		0.95

On 26-Nov-2015, prior to any intra-day change that may have been published, the rating for this security was Overweight, and the adjusted price target was 1.

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of Lloyds Banking Group PLC in the previous 12 months.

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by Lloyds Banking Group PLC.

CE: Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by Lloyds Banking Group PLC.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from Lloyds Banking Group PLC in the past 12 months.

E: Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from Lloyds Banking Group PLC within the next 3 months.

I: Barclays Bank PLC and/or an affiliate is party to an agreement with Lloyds Banking Group PLC for the provision of financial services to Barclays Bank PLC and/or an affiliate.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by Lloyds Banking Group PLC and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from Lloyds Banking Group PLC within the past 12 months.

L: Lloyds Banking Group PLC is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: Lloyds Banking Group PLC is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: Lloyds Banking Group PLC is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

Valuation Methodology: We value the UK banks using the traditional Gordon Growth model to determine the price to book value for franchise at Dec 2020. We then add or subtract the capital surplus/deficit versus our steady state capital forecast at that date. We discount this back to the Price Target date and add the present value of dividends until the valuation date. For the UK banks we use a cost of equity of 10% and a terminal growth of 2%.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key downside risks: Factors in a weaker UK macro outlook with NIM compression as rates stay lower and the SVR book continues to run off, loan contraction, a miss on the cost:income target and impairments over double the cross-cycle average cited by the company.

IMPORTANT DISCLOSURES CONTINUED

Royal Bank of Scotland Group PLC (RBS LN / RBS.L)

Stock Rating

Industry View


GBP 225 (26-Nov-2018)

OVERWEIGHT

NEUTRAL

Rating and Price Target Chart - GBP (as of 26-Nov-2018)

Currency=GBP



Publication Date	Closing Price	Rating	Adjusted Price Target
26-Oct-2018	2.25		3.40
06-Sep-2018	2.48		3.30
10-May-2018	2.87		3.25
14-Mar-2018	2.58	Overweight	3.10
12-Mar-2018	2.63	Coverage Dropped	
02-May-2017	2.65		2.60
20-Feb-2017	2.59	Equal Weight	2.50
05-Jan-2017	2.31		2.00
31-Oct-2016	1.89		1.75
27-Jun-2016	1.74	Underweight	2.00
03-May-2016	2.23		2.70
01-Feb-2016	2.49		2.90
11-Jan-2016	2.80		3.15

On 26-Nov-2015, prior to any intra-day change that may have been published, the rating for this security was Equal Weight, and the adjusted price target was 4.

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by Royal Bank of Scotland Group PLC.

CE: Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by Royal Bank of Scotland Group PLC.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from Royal Bank of Scotland Group PLC in the past 12 months.

I: Barclays Bank PLC and/or an affiliate is party to an agreement with Royal Bank of Scotland Group PLC for the provision of financial services to Barclays Bank PLC and/or an affiliate.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by Royal Bank of Scotland Group PLC and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from Royal Bank of Scotland Group PLC within the past 12 months.

L: Royal Bank of Scotland Group PLC is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: Royal Bank of Scotland Group PLC is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: Royal Bank of Scotland Group PLC is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

Valuation Methodology: We value the UK banks using the traditional Gordon Growth model to determine the price to book value for franchise at Dec 2020. We then add or subtract the capital surplus/deficit versus our steady state capital forecast at that date. We discount this back to the Price Target date and add the present value of dividends until the valuation date. For the UK banks we use a cost of equity of 10% and a terminal growth of 2%.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key downside risks: Factors in a weaker UK macro outlook with NIM compression as rates stay lower, loan contraction, a miss on the cost:income target, higher impairments and costly resolution of legacy items.

IMPORTANT DISCLOSURES CONTINUED

Standard Chartered PLC (STAN LN / STAN.L)

GBP 616 (26-Nov-2018)

Stock Rating


UNDERWEIGHT

Industry View

NEUTRAL

Rating and Price Target Chart - GBP (as of 26-Nov-2018)

Currency=GBP



Publication Date	Closing Price	Rating	Adjusted Price Target
01-Aug-2018	6.83		6.00
03-May-2018	7.42		6.50
14-Mar-2018	7.64	Underweight	6.85
12-Mar-2018	7.82	Coverage Dropped	
26-May-2017	7.34		6.20
06-Mar-2017	7.42		5.75
06-Sep-2016	6.39	Underweight	5.20
10-Feb-2016	4.07	Equal Weight	5.00

On 26-Nov-2015, prior to any intra-day change that may have been published, the rating and price target for this security were suspended.

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of Standard Chartered PLC in the previous 12 months.

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by Standard Chartered PLC.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from Standard Chartered PLC in the past 12 months.

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by Standard Chartered PLC and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from Standard Chartered PLC within the past 12 months.

L: Standard Chartered PLC is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: Standard Chartered PLC is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: Standard Chartered PLC is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

Valuation Methodology: We value the UK banks using the traditional Gordon Growth model to determine the price to book value for franchise at Dec 2020. We then add or subtract the capital surplus/deficit versus our steady state capital forecast at that date. We discount this back to the Price Target date and add the present value of dividends until the valuation date. For the UK banks we use a cost of equity of 10% and a terminal growth of 2%.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key upside risks: Faster growth across Standard Chartered's footprint, together with a stronger recovery in commodity prices and faster US rate rises, would increase our confidence in Standard Chartered growing revenues sufficiently to drive a recovery in profitability.

DISCLAIMER:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ("Third-Party Content"). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

All Barclays research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No:

+91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by either Barclays Bank PLC, Barclays Capital Inc., Barclays Capital Securities Limited or Barclays Capital Asia Limited. None of Barclays Bank PLC, nor any of the other referenced Barclays group entities, hold an Australian financial services licence and instead they each rely on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2018). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

